GLP1 News and Research

RSS
New diabetes drugs linked to increased risk of lower-limb amputation and ketoacidosis

New diabetes drugs linked to increased risk of lower-limb amputation and ketoacidosis

Chemist finds how to control blood sugar without usual side effects

Chemist finds how to control blood sugar without usual side effects

Diabetes patients least likely to follow medical advice regarding medication due to side effects

Diabetes patients least likely to follow medical advice regarding medication due to side effects

Researchers examine human mutations' impact on therapeutic effect of medicine

Researchers examine human mutations' impact on therapeutic effect of medicine

Novel, ultra-rare damaging genetic variants may contribute to eating disorders

Novel, ultra-rare damaging genetic variants may contribute to eating disorders

Gene-therapy administered through skin transplants could enable treatment of many diseases

Gene-therapy administered through skin transplants could enable treatment of many diseases

Review highlights effective treatment options for managing patients with T2D and osteoporosis

Review highlights effective treatment options for managing patients with T2D and osteoporosis

Triple hormone reduces body weight, improves insulin sensitivity

Triple hormone reduces body weight, improves insulin sensitivity

GLP-1 hormone can predict metabolic efficacy of gastric bypass

GLP-1 hormone can predict metabolic efficacy of gastric bypass

TSRI scientists study 3-D structure of glucagon receptor for treatment of diabetes

TSRI scientists study 3-D structure of glucagon receptor for treatment of diabetes

GLP1 medications appear to protect diabetic patients from heart failure

GLP1 medications appear to protect diabetic patients from heart failure

Redpoint Bio fourth quarter revenues are $0.7 million for 2010

Redpoint Bio fourth quarter revenues are $0.7 million for 2010

TransPharma completes ViaDor-GLP1 agonist Phase 1b trial for treatment of type II diabetes

TransPharma completes ViaDor-GLP1 agonist Phase 1b trial for treatment of type II diabetes

Oramed announces publication of GLP-1 analog formulation in Journal of Diabetes

Oramed announces publication of GLP-1 analog formulation in Journal of Diabetes

Redpoint Bio decreases third quarter net loss to $1.8 million

Redpoint Bio decreases third quarter net loss to $1.8 million

TransPharma Medical completes ViaDerm-GLP1 agonist Phase 1a trial for type II diabetes

TransPharma Medical completes ViaDerm-GLP1 agonist Phase 1a trial for type II diabetes

Redpoint Bio issued patent that covers high-throughput screening technology

Redpoint Bio issued patent that covers high-throughput screening technology

Redpoint Bio announces revenue of $1.9M for full-year 2009

Redpoint Bio announces revenue of $1.9M for full-year 2009

How and why weight-reducing surgery sometimes cures diabetes

How and why weight-reducing surgery sometimes cures diabetes

Pine nut oil boosts appetite suppressors

Pine nut oil boosts appetite suppressors